Vitamin D deficiency, Chronic kidney failure.
Conditions
Interventions
80 patients will be included and suplementation with vitamin D3 (cholecalciferol) will follow the guidelines of clinical practice guide from the National Kidney Foundation (NFK) Kidney Disease Outcome
dietary supplement
Sponsors
Universidade Federal de São Paulo
Universidade Federal de São Paulo
Eligibility
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients in stages 3 and 4 CKD (creatinine clearance between 59 and 15 mL/min/1.73m ²); Both genders; Aged between 18 and 75 years; Patients in the conservative treatment of CKD for at least 3 months; With serum 25 (OH) D3 <30 ng/mL: And who agree to participate.
Exclusion criteria
Exclusion criteria: Patients with nephrotic syndrome, liver disease, neoplastic, autoimmune or infectious activity and were seropositive for HIV; Patients who received any supplements or vitamin D analogues, corticosteroids and immunosuppressive drugs in the last 3 months; Patients with hypercalcemia (ionized calcium> 1.40 mmol/L) and/or serum parathormone (PTH) levels> 500 pg/mL; Patients immobilized in the last three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Beneficial effect of vitamin D3 supplementation on the cardiovascular system. The cardiovascular parameters will be assessed by ambulatory blood pressure monitoring(ABPM) and helical computed tomography coronary carried out at the beginning and end of the study. It is hope that with suplementation reduce blood pressure levels, both systolic and diastolic.Regarding calcification is expected to occur coronary plaque stabilization or even regression. About the laboratory tests is expected to decrease PTH values, increase the values of 25(OH)D above 30ng/mL, and calcium values remain in the normal range. | — |
Secondary
| Measure | Time frame |
|---|---|
| Beneficial effect of vitamin D3 supplementation in control of the secondary hyperparathyroidism in chronic kidney disease. Evaluation will be performed by laboratoy tests of total and ionized calcium, serum phosphorus and PTH-intact.About the laboratory tests is expected to decrease PTH values, increase the values of 25(OH)D above 30ng/mL, and calcium values remain in the normal range.;Supplementation with vitamin D3 is expected to control secondary hyperparathyroidism, as assessed by laboratory tests of PTH-intact. About the PTHi, is expected to decrease yours values.It is also expected to present that there is no causal relationship between supplementation and hypercalcemia. Laboratory tests will be collected monthly until the sixth month of supplementation, after six months every two months.It is expected that the values calcium ??remain in normal range. | — |
Countries
Brazil
Contacts
Public ContactRoberta Pillar
Universidade Federal de Sao Paulo
Outcome results
None listed